Ron Bose
Affiliations: | Molecular Oncology | Washington University School of Medicine, St. Louis, MO, United States |
Google:
"Ron Bose"Children
Sign in to add trainee| Timothy S Collier | post-doc | 2010-2013 | Washington University School of Medicine |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Meric-Bernstam F, Raghav KPS, Sweeney CJ, et al. (2025) ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. OF1-OF10 |
| Tarantino P, Tayob N, Villacampa G, et al. (2024) Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2302170 |
| Iglesia MD, Jayasinghe RG, Chen S, et al. (2023) Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages. Biorxiv : the Preprint Server For Biology |
| Sweeney CJ, Hainsworth JD, Bose R, et al. (2023) MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2202636 |
| Cheng X, Sun Y, Highkin M, et al. (2023) Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 -Cyclin D1 axis driving tumorigenesis and drug resistance. Cancer Research |
| Hensing WL, Gerratana L, Clifton K, et al. (2023) Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Chan A, Ruiz-Borrego M, Marx G, et al. (2022) Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer. Breast (Edinburgh, Scotland). 67: 94-101 |
| Chudnovsky Y, Kumar RD, Schrock AB, et al. (2022) Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2-Targeted Therapy. Jco Precision Oncology. 1: 1-9 |
| Ma CX, Luo J, Freedman RA, et al. (2022) The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2 mutated, non-amplified metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Bose R, Ma CX. (2021) Breast Cancer, Mutations, and Overcoming Drug Resistance. The New England Journal of Medicine. 385: 1241-1243 |